Cash Converters Intl.

Similar documents
BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS

Consolidated Operations Group (COG)

Praemium (PPS) COMPANY REPORT. Model performance

Noni B (NBL) BUY: FY18e EBITDA +12.8% Key points. Risks and catalysts

Regional Express Holdings Ltd REX

Resetting expectations

Crowd Mobile (CM8) A Strong FY17 Result. 24 March Bell Potter Small Cap Team

Vita Group (VTG) COMPANY REPORT. Vitality in question

ContextVision. Expecting solid results and awaiting progress update on research program

MotorCycle Holdings (MTO) New HOLD: Harley still lacking traction. Key points. Risks and catalysts

PRICE $1.30 Regional Express Holdings Ltd REX

Noni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts

ContextVision. Neutral stance maintained after 3Q. 3Q14 Results analysis November 5 th 2014 Share price: NOK Target: NOK 24.

ContextVision. Solid 2Q and more details on the contract awaited. August 18 th 2014 Share price: NOK Target: NOK Risk: Medium.

AtCor Medical Holdings Limited (ACG)

Praemium (PPS) COMPANY REPORT. Quartermaster

Asset revaluation driven by almonds

2014 E 2015 E 2016 E 2017 E

MNF Group Limited (MNF)

PRICE $1.16 Regional Express Holdings Ltd REX

Insurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates

ISRA VISION Neutral

China Renewable Energy Investment Ltd (987_HK)

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Adacel Technologies (ADA)

Platinum Asset Management (PTM)

Sirtex Medical. Healthy dose sales. Earnings and target price revision. Price catalyst. Catalyst: FY16 result on the 24th of August

SABIC Overall strong performance

Wisr Ltd. New products to underpin growth

SAFARICOM LTD EARNINGS UPDATE MAY 2016

Recycling assets at a premium. Vector to sell non-auckland gas assets at a premium. We view the transaction as value accretive

Family Zone Cyber Safety Limited (FZO) Company Update. Investment Summary. Investment Highlights. Investment Recommendation

DICKER DATA LIMITED ANNUAL RESULTS

Genex Power (GNX) COMPANY REPORT. NAIF lined up for Stage 2

2017 half year results investor presentation

MATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation

Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions

Zain KSA bogged down by high debt

Wisr Ltd (DirectMoney)

Telstra Corporation. Vodafone better, but far from good A$6.43 AUSTRALIA. Event. Impact. Earnings and target price revision.

Nanosonics (NAN) 1H17: Cash earnings beat grabs attention. Key points

Eddie Stobart Logistics

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

Vista Group International

Auckland International Airport

Centrale del Latte d'italia

Advanced Vision Techn Buy

COUNTRY: GREECE PRICE: 4.60 SECTOR: RETAIL ATHEX Index: 2, DATE: September 21 st, 2004 TARGET PRICE: 5.8

Appen Limited (APX-AU) 29 August 2017

BDI BioEnergy Internat Buy

Tech Mahindra. 1QFY18 Result Update. Steps in the right direction, compelling valuation. Sector: Technology CMP: ` 385. Recommendation: Buy

SomnoMed (SOM) BUY: US channel conflicts abating in Q4. Key points. Risks and catalysts

Results Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013

SingTel. Earnings and target price revision. Price catalyst. Action and recommendation. Maintain Outperform.

1 November 2017 M1 Kliniken AG. FIRST BERLIN Equity Research. Update following

Wisr Ltd (DirectMoney)

SeaLink Travel Group (SLK)

Result Focus. Pioneer Credit (PNC) Monday, 27 February 2017

Vodafone Qatar (VFQS)

Rajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer

Platinum Asset Management

APN Outdoor Group (APO)

SMARTPAY (ASX SMP) Presented by Bradley Gerdis (CEO)

Freedom Insurance (FIG)

Fisher & Paykel Healthcare

FY18 Results Presentation Bravura Solutions Limited. 28 August 2018

For personal use only. Investor Presentation November 2012

HAEMATO AG SOLID UPTICK IN H2 SALES AND EBIT MARGIN. FIRST BERLIN Equity Research PRICE TARGET H A

Sims Metal Management

Quick take. Aditya Birla Nuvo BUY. Deep Value. Valuation Methodology. Exhibit 1: ABNL s Business Structure

Cochlear. Roberts replaced A$88.66 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst. Action and recommendation

FY Alliance Aviation Services Limited Results Presentation. August 2018

Tenaga Nasional Bonus earnings not sustainable

Strong Second Half Performance

Stock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016

Beacon Lighting Group Limited RESULTS PRESENTATION HI F Y 20 15

E 2016E 2017E

Trevi Group Italy Capital goods

CSL: Global plasma report

UGL. Driving growth in DTZ. Earnings and target price revision. No change. Price catalyst. Action and recommendation

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

Company Review 1300SMILES. Corporate Activity Dental Partners. ONT A$6.72 (TP $6.26) Recommendation Hold (no change) Risk Assessment Medium

LUCISANO MEDIA GROUP. New partner for Lucisano. Buy (maintained) Company Update

Narnolia Securities Ltd. ADITYA GUPTA 15-Feb-18

OneVue Holdings (OVH)

Petro Rabigh Shutdown marred Q2 results

A SHORT SMARTPAY. ASX Small / Mid Cap Conference. 6 September Presented by: Bradley Gerdis. September 8 th 2015

Centrale del Latte d'italia

Ramsay Health Care. France begins to bite A$66.37 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

Saudi Ceramic Expansion plan key growth driver

Wipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold

Nanosonics Limited. Australia Health Care Equipment & Supplies. Growth outlook unchanged. Earnings Forecasts. Source Company, LINWAR Research

Dangote Cement Plc. Improved Product Pricing Boosts Earnings. Nigeria Equities Industrial Goods April 3, 2018

FLASH NOTE Welspun India 31 Jan 17

CogState Limited (CGS)

Zespri. Vote for change and SunGold licence sales underpin a strong outlook COMPANY RESEARCH. Private Wealth Research

Mobily high growth phase continues

TCL Communication (2618 HK) Painful transition period. Buy (Maintain) Target Price HK$2.33 Up/downside +28.5% Current price HK$1.

MMC MMC MK Sector: Utilities

High-Tech. Company Data. Data Source: FactSet

Transcription:

MICROCAP COMPANY RESEARCH Cash Converters Intl. 22 nd November 2012 GICS: Diversified Financials Consumer Finance 1Q13 Trading Update RECENT NEW S Cash Converters [ASX:CCV] recently provided a trading update for the first quarter of FY13 showing strong growth in its UK personal loan product and operating earnings coming ahead of management s expectations. U P D A T E R E P O R T Event 1Q13 Trading Update: Unaudited EBIT in the first quarter was 43% higher than pcp at $14.2m. UK loan books performing strongly: UK personal loan book grew from 12.7m to 16.7m in November driven by rollout into corporate stores and customer penetration. Profitability has also improved with bad debt levels stabilising. We believe the UK is the real growth driver for the business going forward. Australian loan book growing solidly: Personal loan book has grown from $67.6m to $72.1m by November. Strong growth from the online platform has driven this. We are impressed by continued solid growth from a mature book. Our view Upward revision to our NPAT forecasts: Our FY13 NPAT forecast is increased from $34.8m to $37.9m and FY14 numbers from $37.6m to $41.2m. Our dividend forecasts are maintained at 3.75c and 4.0c respectively. CCV BUY Price Objective: $1.22 Last traded A$ $0.955 Market Cap A$ m 368.0 Nº of Shares m 385.4 2012A EPS 7.6 2013F EPS 9.8 2013F PE x 9.7 2013F EV/EBITDA x 6.3 2013F DPS 3.75 2013F Div Yield % 3.9 Sales 2012A m 235.2 Sales 2013F m 278.9 EBITDA 2012A m 48.1 EBITDA 2013F m 62.2 NPAT 2012A* m 29.4 NPAT 2013F m 37.9 *2012F NPAT is reported NPAT (inclusive of one-off items) Share Price 12month Valuation Recommendation We maintain a BUY recommendation and raise our price objective to $1.22 from $1.01. This represents a 27.7% premium over the last traded price of $0.955. Stabilisation of bad debt levels in the UK personal loan book and improved profitability allows us to upgrade our FY13 earnings forecasts. Increase in the growth assumptions of the Australian personal loan book further underlies our forecasts. Analyst Shuo Yang Tel: (612) 9232 7494 syang@microequities.com.au IMPO RTANT DISCLO SURE INFORMAT ION AT T HE END OF THIS REPORT

1Q13 TRADING UPDATE...ITS ALL ABOUT THE UK Cash Converters recently provided a first quarter trading update with unaudited first quarter EBIT up 43% to $14.2m from pcp. The UK personal loan book is growing at rates faster than we had envisaged and profitability improving following a stabilisation in bad debt levels. The loan book has grown to 15.3m (September 2012) and at the recent AGM, the book had grown to around 16.7m (November 2012) from 12.7m at the end of FY12. UK personal loan EBIT during the quarter was 155.4% higher than pcp as the book gains scale and matures. We expect strong growth to continue with rollout of the loan product into 20 UK stores in FY13 and increased penetration and repeat customers. Profitability will also continue to improve with maturity of the book and increased repeat customers. 1Q13 unaudited EBIT is 43% higher than pcp. Growth and profitability of the UK personal loan book has surprised on the upside. Growth in the Australian personal loan book continues with the loan book rising from $67.6m at the end of FY12 to $72.1m in November 2012. Bad debt levels remained relatively stable at around 5.6% of principal loaned. Driving this strong growth has been the personal loans through its online platform. The online personal loan book in Australia is now around $13.2m and 1.0m for UK personal loans. Australian personal loan book also growing ahead of our expectations. The company also continued with the expansion of its corporate store network with two stores acquired in the UK (currently 61 corporate stores and 161 franchise stores) and two new corporate store openings in Australia (currently 44 corporate stores and 103 franchise stores). CHANGES TO OUR FORECASTS Figure 1: CCV Earnings revisions Figures in A$ million unless stated FY12A FY13F (OLD) FY13F (NEW) % Revision FY14F (OLD) FY14F (NEW) % Revision Revenue 234.4 274.2 279.9 +2.1% 294.2 300.8 +2.2% Operating Expenses -186.2-216.5-217.7-231.0-232.5 EBITDA 48.1 57.8 62.2 63.2 68.3 % Chg YoY 15% 20% 29% 9% 10% EBITDA Margin 21% 21% 22% 21% 23% We upgrade our FY13 and FY14 numbers in light of the 1Q13 trading update and positive tone from management. Depr & Amortisation -4.3-5.9-5.9-7.4-7.4 EBIT 43.8 51.9 56.3 +8.5% 55.8 61.0 +9.3% EBIT Margin 19% 19% 20% 19% 20% Net Interest Expense -2.4-2.2-2.2-2.1-2.1 Profit Before Tax 41.4 49.7 54.1 +8.9% 53.7 58.8 +9.5% Tax Benefit (Expense) -12.0-14.9-16.2-16.1-17.6 Reported NPAT 29.4 34.8 37.9 37.6 41.2 Add back: One-off items 3.2 0.0 0.0 0.0 0.0 Underlying NPAT 32.6 34.8 37.9 +8.9% 37.6 41.2 +9.6% Source: Company data, Microequities estimates 22 nd November 2012 www.microequities.com.au 2

We have increased our forecast growth rates for the Australian and UK personal loan books to account for the strong 1Q13 trading performance. In FY13 we expect the UK personal loan book to grow by around 73% to circa 22m (our previous forecast was 20m), driven by rollout into further stores and increased customer penetration. We expect the Australian loan book to grow by around 15% to $77.9m with its online platform and legislation certainty paving the way for growth. We have increased our growth assumptions for the UK and Australian personal loan books. We upgrade our FY13 and FY14 forecasts to account for improvements in profitability and faster rate of growth in the personal loan books. Our FY13 NPAT forecast is increased from $34.8m to $37.9m and FY14 forecast from $37.6m to $41.2m. Credit reform legislations in Australia take effect in FY14 but we believe continued penetration and improving profitability of the UK operations will more than offset this impact. Our dividend forecasts of 3.75c and 4.0c for FY13 and FY14, respectively, are maintained. 22 nd November 2012 www.microequities.com.au 3

VALUATION RECOMMENDATION DCF Valuation Our DCF model provides us with a $1.34 valuation for CCV, representing a 40% premium to the last traded price. We have used a fundamental BETA of 0.98, a WACC of 10.13% and long-term growth rate of 1%. DCF Valuation Breakup Net Debt 5% Key Assumptions Equity Beta: 0.98 Debt: $42.6m Terminal Value 43% Present Value 52% Risk free rate: 3.22% K d: 6.3% Return on Equity: 10.57% WACC: 10.13% LT Growth Rate: 1.00% Relative EV/EBITDA Valuation We have undertaken a relative valuation using the most appropriate peer comparisons in the consumer financials sector. Using a forecast FY13 PE multiple of 10x, we have derived a relative valuation of $1.10 per share, representing a 15% premium to the last traded price. Peer group financial summary (as at 21/11/2012) 15.8 11.2 9.5 8.4 10.0 9.7 SIV FXL TGA MNY CCV Investment Opinion We maintain a BUY recommendation and increase our price objective to $1.22 from $1.01. The price objective is based on a combination of our DCF valuation of $1.34 and our relative peer valuation of $1.10 which we have applied a peer group average forward PE of 10x. Improved profitability and our assumption for faster growth in the UK personal loan book leads us to upgrade FY13 and FY14 earnings forecasts. 22 nd November 2012 www.microequities.com.au 4

PRICE OBJECTIVE & RECOMMENDATION HISTORY Changes to recommendations and/or price objectives Date Recommendation Price at time of Rec Price Objective 22/11/2012 BUY $0.955 $1.22 04/09/2012 BUY $0.795 $1.01 02/03/2012 BUY $0.60 $0.75 18/01/2012 STRONG BUY $0.52 $0.78 22 nd November 2012 www.microequities.com.au 5

FINANCIAL SUMMARY P R O F I T & L O S S S U M M A R Y ( $ m ) P R O F I T A B I L I T Y R A T I O S Year Ending June 2012A 2013F 2014F Year Ending June 2012A 2013F 2014F Revenue 234.4 279.9 300.8 Sales 235.2 278.9 299.7 Op. Expense -186.2-217.7-232.5 % Chg YoY 26% 19% 7% EBITDA 48.1 62.2 68.3 Price/Sales 1.6x 1.3x 1.2x % Chg YoY 15% 29% 10% EPS (cents) 7.6 9.8 10.7 % Margin 21% 22% 23% % Chg YoY 6% 29% 9% Depreciation & Amortisation -4.3-5.9-7.4 P/E 12.5x 9.7x 8.9x EBIT 43.8 56.3 61.0 Enterprise Value 394.3 394.3 394.3 % Margin 19% 20% 20% EV/EBIT 9.0x 7.0x 6.5x Net Interest Expense -2.4-2.2-2.1 EV/EBITDA 8.2x 6.3x 5.8x PBT 41.4 54.1 58.8 DPS 3.50 3.75 4.00 Tax -12.0-16.2-17.6 Dividend Yield 3.7% 3.9% 4.2% NPAT 29.4 37.9 41.2 ROE 16% 15% 14% Debt to Assets 16% 14% 12% Debt to Equity 23% 18% 15% B A L A N C E S H E E T S U M M A R Y ( $ m ) C A S H F L O W S U M M A R Y ( $ m ) Year Ending June 2012A 2013F 2014F Year Ending June 2012A 2013F 2014F Cash & cash equivalents 16.4 24.3 39.2 EBITDA $48.1 $62.2 $68.3 Trade and other receivables 10.9 12.5 14.4 Decre./(Incr.) in work. Cap -$5.0 -$3.0 -$2.2 Inventories 17.1 19.6 21.2 Net Int. (Paid)/Rec -$1.7 -$2.2 -$2.1 Other Current Assets 91.1 119.9 138.4 TaxesPaid -$15.3 -$16.2 -$17.6 Total Current Assets 135.5 176.3 213.2 Incr/(decr) in provisions $0.6 $0.0 $0.0 Other financial assets 4.0 4.0 4.0 Other Op. Cash items -$3.7 $0.0 $0.0 Trade and other receivables 6.1 6.1 6.1 Cash from Operations $23.1 $40.8 $46.3 Property, Plant & Equipment 19.6 28.1 31.7 CAPEX -$11.9 -$19.8 -$16.1 Intangible assets 15.5 28.3 30.6 Disposals/(Acquisitions) -$6.1 $0.0 $0.0 Deferred tax assets 4.8 4.8 4.8 Other Inv. Cash Flows -$1.4 $0.0 $0.0 Other Non-Current Assets 77.2 77.2 77.2 Loans to/from other ent. $0.6 $0.0 $0.0 Total Non-Current Assets 127.3 148.6 154.4 Cash Flow From Invst. -$18.8 -$19.8 -$16.1 TOTAL ASSETS 262.7 324.9 367.6 Incr/(Decr) in Equity $0.0 $0.0 $0.0 Trade and other payables 19.6 20.8 22.0 Incr/(Decr) in Debt $20.4 $1.4 $0.1 Borrowings 11.3 11.3 11.3 Ord, Dividend paid -$11.1 -$14.5 -$15.4 Current tax liabilities 7.1 8.1 8.8 Preferred dividends $0.0 $0.0 $0.0 Deferred establishment fee 4.1 4.1 4.1 Other Fin. Cash Flow -$0.3 $0.0 $0.0 Provisions 2.7 2.7 2.7 Cash Flow From Fin $9.0 -$13.0 -$15.3 Total Current Liabilities 44.7 44.2 46.2 Net Incr/(Dcr) in cash $13.2 $7.9 $14.9 Borrowings 31.4 32.8 32.9 Forx & Disc. Op. -$0.6 $0.0 $0.0 Provisions.1.1.1 Net Inc/(Decr) Cash $12.6 $7.9 $14.9 Total Non-Current Liabilities 31.4 32.9 32.9 Equity FCF $11.1 $12.4 $28.5 TOTAL LIABILITIES 76.1 77.1 79.1 NET ASSETS 186.6 247.8 288.5 22 nd November 2012 www.microequities.com.au 6

IMPORTANT DISCLOSURE INFORM ATION: Produced by Microequities Pty Ltd in accordance with section 949A of the Corporations Act 2001. Any recipient of the information contained in this document should note that the information is general advice in respect of a financial product and is not personal advice. Accordingly, the recipient should note that a) the advice has been prepared without taking into account the recipient s objectives, financial situation or need; and b) as a corollary, the recipient should, before acting o n the advice, consider the appropriateness of the advice, h aving regard to the recipient s objectives, financial situation and needs. Although Microequities Pty Ltd (Microequities) considers the advice and information contained in the document to be accurate and reliable, Microequities has not independently verifi ed the information contained in the document which is derived from publicly available sources. Microequities assumes no responsibility for updating any advice or recommendation contained in this document or for correcting any error or admission, which may become apparent after the document has been issued. Microequities does not give any warranty as to the accuracy, reliability or completeness of advice or information contained in this document. Except in the case where liability under any statute cannot be excluded, Microequities, its employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Microequities, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Act 2001 may receive remuneration from transactions involving financial products referred to in this document. Microequities and its associates (as defined in Chapter 7 of the Corporations Law), officers, directors, employees and agents, companies to which this document refers and may trade in the securities mentioned either as principal or agent. Furthermore, the trading by its associates may not necessarily correspond to the recommendation been provided in this document. RECOMMENDATION GUIDE Recommendation Market Price undervalued/overvalued to Microequities price objective Strong Buy Above 40% Buy 20 to 40% Hold 0 to 20% Sell 0 to -20% Strong Sell Greater than 20% ADDITION AL VOLUNTARY DISCLOSURE BY MICROEQUITIES* Investment Banking Staff Interest Analyst personal Interest Equity Stake By Microequities Disclosure to Company Business Relationship NO NO NO NO NO * To promote transparency, Microequities voluntarily discloses potential conflict of interests covered by this research document. Additional disclosure: - Microequities Pty Ltd has a research distribution agreement with Cash Converters International Limited. 22 nd November 2012 microequities.com.au